Key result
Mesalamine therapy in a 19-year-old male with Crohn's disease was associated with the development of myocarditis, which resolved after discontinuing the drug.
Case Report (n=1)
Highlights a rare case of mesalamine-induced myocarditis in a young patient with Crohn's disease, emphasizing the importance of recognizing this drug-hypersensitivity reaction and discontinuing the offending agent.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to consider mesalamine in myocarditis differentials for IBD; hypothesis-generating and requires larger studies for causality.
Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. We present the case of a 19-year-old male who developed chest pain two weeks after beginning mesalamine therapy. The electrocardiogram showed slight ST-segment elevation with upward concavity in the inferolateral leads; blood tests demonstrated elevated troponin I and the echocardiogram revealed moderately depressed left ventricular systolic function with global hypocontractility. Cardiac magnetic resonance imaging confirmed the diagnosis of myocarditis, revealing multiple areas of subepicardial fibrosis. The onset of symptoms after mesalamine, and improvement of chest pain, cardiac biomarkers and left ventricular systolic function after discontinuing the drug, suggest that our patient suffered from a rare drug-hypersensitivity reaction to mesalamine.
No takes yet. Share an insight, caveat, or question.
Braga et al. (2013) conducted a case report in Crohn's disease (n=1). Mesalamine was evaluated on Development of myocarditis. Mesalamine therapy in a 19-year-old male with Crohn's disease was associated with the development of myocarditis, which resolved after discontinuing the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: